Characterization and Management of Cytopenias after Imetelstat Treatment in the IMerge Phase 3 Trial of Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS)

被引：0
|
作者：
Zeidan, Amer M. [1 ,2 ]
Savona, Michael R. [3 ]
Madanat, Yazan F. [4 ]
Fenaux, Pierre [5 ]
Komrokji, Rami S. [6 ]
Jonasova, Anna [7 ]
Illmer, Thomas
Sun, Libo [8 ]
Berry, Tymara [8 ]
Feller, Faye M. [8 ]
Navada, Shyamala [8 ]
Santini, Valeria [9 ,10 ]
Platzbecker, Uwe [11 ]
机构：
[1] Yale Univ, Yale Sch Med, New Haven, CT USA
[2] Yale Univ, Yale Canc Ctr, New Haven, CT USA
[3] Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, Nashville, TN USA
[4] UT Southwestern Med Ctr, Harold C Simmons Comprehens Canc Ctr, Dallas, TX USA
[5] Univ Paris 07, Hop St Louis, Paris, France
[6] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[7] Gen Hosp, Prague, Czech Republic
[8] Geron Corp, Parsippany, NJ USA
[9] Azienda Osped Univ Careggi, MDS UNIT, DMSC, Florence, Italy
[10] Univ Florence, Florence, Italy
[11] Leipzig Univ Hosp, Cellular Therapy & Hemostaseol, Leipzig, Germany
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-180962
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [31] Longer-Term RBC Transfusion Reduction in the Phase 3 MEDALIST Study of Luspatercept in Patients with Lower-Risk MDS (LR-MDS) with Ring Sideroblasts (RS)
    Komrokji, Rami S.
    Sekeres, Mikkael A.
    Zeidan, Amer M.
    Fenaux, Pierre
    Platzbecker, Uwe
    DeZern, Amy E.
    Greenberg, Peter L.
    Savona, Michael R.
    Jurcic, Joseph G.
    Verma, Amit
    Mufti, Ghulam J.
    Buckstein, Rena
    Santini, Valeria
    Laadem, Abderrahmane
    Ito, Rodrigo
    Zhang, Jennie
    Louis, Chrystal U.
    Linde, Peter G.
    Garcia-Manero, Guillermo
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S322 - S322
  • [32] IMerge: Results from a phase 3, randomized, double-blind, placebo-controlled study of imetelstat in patients (pts) with heavily transfusion dependent (TD) non-del(5q) lower-risk myelodysplastic syndromes (LR-MDS) relapsed/refractory (R/R) to erythropoiesis stimulating agents (ESA).
    Zeidan, Amer Methqal
    Platzbecker, Uwe
    Santini, Valeria
    Fenaux, Pierre
    Sekeres, Mikkael A.
    Savona, Michael R.
    Madanat, Yazan F.
    Diez-Campelo, Maria
    Valcarcel, David
    Illmer, Thomas
    Jonasova, Anna
    Belohlavkova, Petra
    Sherman, Laurie Jill
    Berry, Tymara
    Dougherty, Souria
    Shah, Sheetal
    Sun, Libo
    Wan, Ying
    Huang, Fei
    Komrokji, Rami S.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [33] Imetelstat Achieved Prolonged, Continuous Transfusion Independence (TI) in Patients with Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndrome (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs) within the IMerge Phase 2 Study
    Platzbecker, Uwe
    Komrokji, Rami S.
    Fenaux, Pierre
    Zeidan, Amer M.
    Sekeres, Mikkael A.
    Savona, Michael Robert
    Madanat, Yazan F.
    Santini, Valeria
    Van Eygen, Koen
    Raza, Azra
    Germing, Ulrich
    Berry, Tymara
    Dougherty, Souria
    Shah, Sheetal
    Sun, Libo
    Huang, Fei
    Feller, Faye
    Wan, Ying
    Ikin, Annat
    Sherman, Laurie
    BLOOD, 2022, 140 : 1106 - 1108
  • [34] Clinical benefit of luspatercept in patients (pts) with lower-risk MDS (LR-MDS) and high transfusion burden in the phase III MEDALIST study.
    Zeidan, Amer Methqal
    Garcia-Manero, Guillermo
    Dezern, Amy Elizabeth
    Fenaux, Pierre
    Greenberg, Peter L.
    Savona, Michael R.
    Jurcic, Joseph G.
    Verma, Amit
    Mufti, Ghulam J.
    Buckstein, Rena
    Santini, Valeria
    Laadem, Abderrahmane
    Zhang, Jennie
    Rampersad, Anita
    Sinsimer, Daniel
    Louis, Chrystal Ursula
    Linde, Peter G.
    List, Alan F.
    Sekeres, Mikkael A.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [35] ASTX727-03: Phase 1 Study Evaluating Oral Decitabine/Cedazuridine (ASTX727) Low-Dose (LD) in Lower-Risk Myelodysplastic Syndromes (LR-MDS) Patients
    Garcia-Manero, Guillermo
    Bachiashvili, Kimo
    Amin, Harshad
    Traer, Elie
    Pollyea, Daniel A.
    Sallman, David A.
    Al-Kali, Aref
    Cripe, Larry D.
    Berdeja, Jesus G.
    Griffiths, Elizabeth A.
    Mohan, Sanjay R.
    Sano, Yuri
    Oganesian, Aram
    Keer, Harold N.
    Yacoub, Abdulraheem
    BLOOD, 2022, 140 : 1112 - 1114
  • [36] Luspatercept versus epoetin alfa (EA) for treatment (tx) of anemia in ESA-naive lower-risk myelodysplastic syndromes (LR-MDS) patients (pts) requiring RBC transfusions (RBCT): data from the phase 3 COMMANDS study
    Platzbecker, Uwe
    Porta, Matteo Giovanni
    Santini, Valeria
    Zeidan, Amer M.
    Fenaux, Pierre
    Komrokji, Rami S.
    Shortt, Jake
    Valcarcel, David
    Jonasova, Anna
    Dimicoli-Salazar, Sophie
    Tiong, Ing Soo
    Lin, Chien-Chin
    Li, Jiahui
    Zhang, Jennie
    Giuseppi, Ana Carolina
    Kreitz, Sandra
    Pozharskaya, Veronika
    Keeperman, Karen L.
    Rose, Shelonitda
    Shetty, Jeevan K.
    Hayati, Sheida
    Vodala, Sadanand
    Degulys, Andrius
    Paolini, Stefania
    Cluzeau, Thomas
    Garcia-Manero, Guillermo
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 116 - 116
  • [37] IMPACT OF IMETELSTAT TREATMENT ON PROS AND HEALTH CARE RESOURCE UTILIZATION IN HEAVILY TRANSFUSED NON-DEL(5Q) LOWER-RISK MYELODYSPLASTIC SYNDROMES RELAPSED/ REFRACTORY TO ERYTHROPOIESIS STIMULATING AGENTS: IMERGE PHASE 3 TRIAL
    Sekeres, M.
    Santini, V
    Diez-Campelo, M.
    Komrokji, R.
    Fenaux, P.
    Savona, M.
    Madanat, Y.
    Valcarcel-Ferreiras, D.
    Illmer, T.
    Jonasova, A.
    Belohlavkova, P.
    Regnault, A.
    Creel, K.
    Sengupta, N.
    Sherman, L.
    Berry, T.
    Dougherty, S.
    Shah, S.
    Xia, Q.
    Sun, L.
    Wan, Y.
    Huang, F.
    Ikin, A.
    Navada, S.
    Feller, F.
    Zeidan, A.
    Platzbecker, U.
    VALUE IN HEALTH, 2023, 26 (12) : S28 - S29
  • [38] Sustained benefits of imetelstat on patient-reported fatigue in patients with lower-risk myelodysplastic syndromes ineligible for, or relapsed/refractory to, erythropoiesis-stimulating agents and high transfusion burden in the phase 3 IMerge study
    Sekeres, Mikkael A.
    Santini, Valeria
    Diez-Campelo, Maria
    Komrokji, Rami S.
    Fenaux, Pierre
    Savona, Michael R.
    Madanat, Yazan F.
    Valcarcel-Ferreiras, David
    Oliva, Esther Natalie
    Regnault, Antoine
    Creel, Kristin
    Sengupta, Nishan
    Dougherty, Souria
    Shah, Sheetal
    Sun, Libo
    Wan, Ying
    Navada, Shyamala
    Zeidan, Amer M.
    Platzbecker, Uwe
    LEUKEMIA & LYMPHOMA, 2025, 66 (03) : 529 - 534
  • [39] Clinical and Biological Effects of Canakinumab in Lower-Risk Myelodysplastic Syndromes (MDS): Results from a Phase 2 Clinical Trial
    Garcia-Manero, Guillermo
    Adema, Vera
    Urrutia, Samuel
    Ma, Feiyang
    Yang, Hui
    Ganan-Gomez, Irene
    Borthakur, Gautam
    Takahashi, Koichi
    Short, Nicholas
    Issa, Ghayas C.
    Chien, Kelly S.
    Montalban-Bravo, Guillermo
    Joseph, Joby
    Colla, Simona
    BLOOD, 2022, 140 : 2078 - 2080
  • [40] Clinical outcomes and healthcare resource utilization (HCRU) in patients (pts) with lower-risk myelodysplastic syndromes (LR-MDS) reinitiating erythropoiesis-stimulating agents (ESAs) following previous ESA treatment.
    Garcia-Manero, Guillermo
    Matsuno, Rayna K.
    McBride, Ali
    Brown, Thomas D.
    Idryo, Danny
    Broome, Ronda
    Herriman, Autumn
    Johnson, Tiffany
    Wilkinson, Kristiana
    Walters, Sheetal
    Schrag, Andrew
    Johanson, Colden
    Izano, Monika A.
    Mukherjee, Sudipto
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345